ProHance

DRUG4 trials

Sponsors

Askbio Inc., Askbio Inc., AskBio France, Bayer, Bracco Diagnostics, Inc

Conditions

Brain MetastasesCentral Nervous System DiseasesCentral Nervous System NeoplasmsParkinson's DiseaseParkinson’s Disease

Phase 2

(ASK-PD5-CS201) A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s Disease

RecruitingCTIS2023-506519-16-00

Askbio Inc.Parkinson’s Disease

Start: 2025-04-11Target: 55Updated: 2026-01-27

Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

Not yet recruitingCTIS2025-522441-21-00

Askbio Inc., AskBio FranceParkinson's Disease

Target: 12Updated: 2026-04-03

Phase 3

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

CompletedNCT00522951

BayerBrain Metastases

Start: 2007-08-31End: 2008-08-31Updated: 2017-08-28

Unknown Phase

Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

CompletedNCT03750188

Bracco Diagnostics, IncCentral Nervous System Diseases, Central Nervous System Neoplasms

Start: 2018-11-01End: 2019-10-16Updated: 2020-01-23